SAM
RPRX icon

Storebrand Asset Management’s Royalty Pharma RPRX Stock Holding History

Storebrand Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.5M Sell
703,962
-72,680
-9% -$3.78M 0.1% 187
2026
Q1 		$37.3M Sell
776,642
-37,475
-5% -$1.64M 0.11% 180
2025
Q4 		$31.5M Sell
814,117
-97,626
-11% -$3.72M 0.08% 207
2025
Q3 		$32.2M Buy
911,743
+277,851
+44% +$10.1M 0.09% 214
2025
Q2 		$22.8M Sell
633,892
-775
-0.1% -$25.7K 0.07% 265
2025
Q1 		$19.8M Sell
634,667
-164,224
-21% -$5.21M 0.06% 273
2024
Q4 		$20.4M Buy
798,891
+358,663
+81% +$9.51M 0.06% 278
2024
Q3 		$12.5M Sell
440,228
-15,499
-3% -$429K 0.04% 358
2024
Q2 		$12M Buy
455,727
+23,213
+5% +$643K 0.04% 363
2024
Q1 		$13.1M Buy
432,514
+139,704
+48% +$4.12M 0.04% 346
2023
Q4 		$8.23M Buy
292,810
+17,617
+6% +$484K 0.03% 421
2023
Q3 		$7.47M Sell
275,193
-48,436
-15% -$1.44M 0.04% 403
2023
Q2 		$9.95M Sell
323,629
-50,196
-13% -$1.7M 0.05% 369
2023
Q1 		$13.5M Buy
373,825
+153,298
+70% +$5.68M 0.07% 311
2022
Q4 		$8.72M Buy
220,527
+190,086
+624% +$7.93M 0.05% 374
2022
Q3 		$1.22M Buy
30,441
+1,990
+7% +$85K 0.01% 639
2022
Q2 		$1.2M Buy
28,451
+4,551
+19% +$187K 0.01% 655
2022
Q1 		$931K Buy
23,900
+1,378
+6% +$54.1K ﹤0.01% 688
2021
Q4 		$898K Buy
22,522
+8,532
+61% +$331K ﹤0.01% 713
2021
Q3 		$506K Buy
13,990
+8,670
+163% +$337K ﹤0.01% 761
2021
Q2 		$218K Hold
5,320
– – ﹤0.01% 793
2021
Q1 		$232K Buy
+5,320
New +$252K ﹤0.01% 780

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CIA
Caledonia Investments (Australia) Sydney NSW, Australia $2.93B AUM 37.21% 1-Year Est. Return

Storebrand Asset Management's RPRX Position: Q2 2026 in Review

Storebrand Asset Management reduced its Royalty Pharma (RPRX) stake by 9.4% in Q2 2026, selling an estimated $3.78M and leaving 703,962 shares worth $39.5M. The position accounts for 0.1% of the portfolio, ranked #187.

Storebrand Asset Management first reported a position in RPRX in Q1 2021 and has held it in 22 quarters since. 607 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Storebrand Asset Management held 703,962 shares of Royalty Pharma worth $39.5M as of Q2 2026.
  • Storebrand Asset Management sold 72,680 Royalty Pharma shares in Q2 2026, an estimated $3.78M.
  • Royalty Pharma made up 0.1% of Storebrand Asset Management's portfolio in Q2 2026, its #187 holding.
  • Storebrand Asset Management first reported a position in Royalty Pharma in Q1 2021 and has held it in 22 quarters since.
  • 607 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Storebrand Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.